arrow
M

Massimiliano Salati

azienda ospedaliero-universitaria di modena
H指数:22
被引数:1,977

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience

关于免疫治疗时代接受多模式治疗的晚期胆道癌患者的初步报告:一项真实世界多中心经验

2026-03-190
OA
Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study)

ASTEROID研究:辅助De Gramont方案与Xelox化疗在切除胃癌中的真实世界疗效比较:一项倾向性评分匹配分析

2025-07-260
OAAI
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy
2025-01-070
OAAI
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors
2025-01-010
PRE
Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer

整合基因组学和转录组学景观的分析,确定了纤毛基因作为胆管癌的治疗靶点

2024-09-010
PRE
Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study

表达模式、转录状态及肿瘤浸润淋巴细胞(TILs)在治愈性治疗的胆管癌(CCA)患者(pts)中的临床意义:TILBIL研究

2024-09-010
PRE
Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment
2023-06-010
OAAI
Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST

基于免疫炎症的新型列线图的开发和多中心验证,以预测西方可切除胃和胃食管交界处腺癌 (GEA) 的生存率: NOMOGAST

2022-09-161
OAAI
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer
2022-09-0117
PRE
Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience
2022-07-061
PRE
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?

FOLFOXIRI和贝伐单抗在BRAFV600E-mutated转移性结直肠癌患者中的先期获益: 原发肿瘤位置重要吗?

2022-06-039
OA
Encorafenib plus cetuximab treatment in BRAF V600-Emutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
2022-06-019
OAAI